A Merritt1, P Booms1, M-A Shaw1, D M Miller1,2, C Daly2, J G Bilmen1,2, K M Stowell3, P D Allen4, D S Steele5, P M Hopkins1,2. 1. Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, Leeds, UK. 2. Malignant Hyperthermia Unit, St James's University Hospital, Leeds, UK. 3. Institute of Fundamental Sciences, Massey University, Palmerston North, New Zealand. 4. Department of Molecular Biosciences, UC Davis, Davis, CA, USA. 5. School of Biomedical Sciences, University of Leeds, Leeds, UK.
Abstract
BACKGROUND: . Missense variants in the ryanodine receptor 1 gene ( RYR1 ) are associated with malignant hyperthermia but only a minority of these have met the criteria for use in predictive DNA diagnosis. We examined the utility of a simplified method of segregation analysis and a functional assay for determining the pathogenicity of recurrent RYR1 variants associated with malignant hyperthermia. METHODS: . We identified previously uncharacterised RYR1 variants found in four or more malignant hyperthermia families and conducted simplified segregation analyses. An efficient cloning and mutagenesis strategy was used to express ryanodine receptor protein containing one of six RYR1 variants in HEK293 cells. Caffeine-induced calcium release, measured using a fluorescent calcium indicator, was compared in cells expressing each variant to that in cells expressing wild type ryanodine receptor protein. RESULTS.: We identified 43 malignant hyperthermia families carrying one of the six RYR1 variants. There was segregation of genotype with the malignant hyperthermia susceptibility phenotype in families carrying the p.E3104K and p.D3986E variants, but the number of informative meioses limited the statistical significance of the associations. HEK293 functional assays demonstrated an increased sensitivity of RyR1 channels containing the p.R2336H, p.R2355W, p.E3104K, p.G3990V and p.V4849I compared with wild type, but cells expressing p.D3986E had a similar caffeine sensitivity to cells expressing wild type RyR1. CONCLUSIONS: . Segregation analysis is of limited value in assessing pathogenicity of RYR1 variants in malignant hyperthermia. Functional analyses in HEK293 cells provided evidence to support the use of p.R2336H, p.R2355W, p.E3104K, p.G3990V and p.V4849I for diagnostic purposes but not p.D3986E.
BACKGROUND: . Missense variants in the ryanodine receptor 1 gene ( RYR1 ) are associated with malignant hyperthermia but only a minority of these have met the criteria for use in predictive DNA diagnosis. We examined the utility of a simplified method of segregation analysis and a functional assay for determining the pathogenicity of recurrent RYR1 variants associated with malignant hyperthermia. METHODS: . We identified previously uncharacterised RYR1 variants found in four or more malignant hyperthermia families and conducted simplified segregation analyses. An efficient cloning and mutagenesis strategy was used to express ryanodine receptor protein containing one of six RYR1 variants in HEK293 cells. Caffeine-induced calcium release, measured using a fluorescent calcium indicator, was compared in cells expressing each variant to that in cells expressing wild type ryanodine receptor protein. RESULTS.: We identified 43 malignant hyperthermia families carrying one of the six RYR1 variants. There was segregation of genotype with the malignant hyperthermia susceptibility phenotype in families carrying the p.E3104K and p.D3986E variants, but the number of informative meioses limited the statistical significance of the associations. HEK293 functional assays demonstrated an increased sensitivity of RyR1 channels containing the p.R2336H, p.R2355W, p.E3104K, p.G3990V and p.V4849I compared with wild type, but cells expressing p.D3986E had a similar caffeine sensitivity to cells expressing wild type RyR1. CONCLUSIONS: . Segregation analysis is of limited value in assessing pathogenicity of RYR1 variants in malignant hyperthermia. Functional analyses in HEK293 cells provided evidence to support the use of p.R2336H, p.R2355W, p.E3104K, p.G3990V and p.V4849I for diagnostic purposes but not p.D3986E.
Authors: Sylvie Ducreux; Francesco Zorzato; Ana Ferreiro; Heinz Jungbluth; Francesco Muntoni; Nicole Monnier; Clemens R Müller; Susan Treves Journal: Biochem J Date: 2006-04-15 Impact factor: 3.857
Authors: Jerry H Kim; Gail P Jarvik; Brian L Browning; Ramakrishnan Rajagopalan; Adam S Gordon; Mark J Rieder; Peggy D Robertson; Deborah A Nickerson; Nickla A Fisher; Philip M Hopkins Journal: Anesthesiology Date: 2013-11 Impact factor: 7.892
Authors: P M Hopkins; H Rüffert; M M Snoeck; T Girard; K P E Glahn; F R Ellis; C R Müller; A Urwyler Journal: Br J Anaesth Date: 2015-07-18 Impact factor: 9.166
Authors: Stephen G Gonsalves; David Ng; Jennifer J Johnston; Jamie K Teer; Peter D Stenson; David N Cooper; James C Mullikin; Leslie G Biesecker Journal: Anesthesiology Date: 2013-11 Impact factor: 7.892
Authors: E F Gillard; K Otsu; J Fujii; V K Khanna; S de Leon; J Derdemezi; B A Britt; C L Duff; R G Worton; D H MacLennan Journal: Genomics Date: 1991-11 Impact factor: 5.736
Authors: Danielle Carpenter; Christopher Ringrose; Vincenzo Leo; Andrew Morris; Rachel L Robinson; P Jane Halsall; Philip M Hopkins; Marie-Anne Shaw Journal: BMC Med Genet Date: 2009-10-13 Impact factor: 2.103
Authors: D M Miller; C Daly; E M Aboelsaod; L Gardner; S J Hobson; K Riasat; S Shepherd; R L Robinson; J G Bilmen; P K Gupta; M-A Shaw; P M Hopkins Journal: Br J Anaesth Date: 2018-08-17 Impact factor: 9.166
Authors: Tanya R Cully; Rocky H Choi; Andrew R Bjorksten; D George Stephenson; Robyn M Murphy; Bradley S Launikonis Journal: Proc Natl Acad Sci U S A Date: 2018-07-23 Impact factor: 11.205
Authors: Remai Parker; Anja H Schiemann; Elaine Langton; Terasa Bulger; Neil Pollock; Andrew Bjorksten; Robyn Gillies; David Hutchinson; Richard Roxburgh; Kathryn M Stowell Journal: J Neuromuscul Dis Date: 2017